 Luisa Mestroni
Concepts (560)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 88 | 2023 | 344 | 10.450 |
Why?
| | Cardiomyopathies | 35 | 2023 | 299 | 6.460 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 23 | 2023 | 29 | 6.240 |
Why?
| | Arrhythmias, Cardiac | 31 | 2023 | 277 | 4.410 |
Why?
| | Myocytes, Cardiac | 24 | 2023 | 472 | 3.910 |
Why?
| | Lamin Type A | 18 | 2023 | 39 | 2.790 |
Why?
| | Heart Failure | 32 | 2023 | 1969 | 2.780 |
Why?
| | Mutation | 40 | 2023 | 3457 | 2.020 |
Why?
| | Cardiomyopathy, Hypertrophic | 14 | 2023 | 119 | 2.010 |
Why?
| | Nanotubes, Carbon | 6 | 2022 | 44 | 1.840 |
Why?
| | Myocardium | 22 | 2023 | 970 | 1.810 |
Why?
| | Tissue Engineering | 6 | 2020 | 362 | 1.660 |
Why?
| | Muscle Proteins | 7 | 2020 | 219 | 1.520 |
Why?
| | Death, Sudden, Cardiac | 18 | 2023 | 166 | 1.500 |
Why?
| | Phenotype | 31 | 2023 | 3003 | 1.440 |
Why?
| | Filamins | 5 | 2023 | 16 | 1.420 |
Why?
| | Genetic Predisposition to Disease | 22 | 2023 | 2275 | 1.380 |
Why?
| | Tissue Scaffolds | 6 | 2022 | 184 | 1.320 |
Why?
| | Electrocardiography | 17 | 2023 | 556 | 1.300 |
Why?
| | Genetic Variation | 6 | 2021 | 926 | 1.300 |
Why?
| | Cell Adhesion | 11 | 2021 | 443 | 1.160 |
Why?
| | Genetic Testing | 13 | 2021 | 389 | 1.150 |
Why?
| | Heart | 10 | 2021 | 631 | 1.140 |
Why?
| | Sarcomeres | 6 | 2021 | 91 | 1.040 |
Why?
| | Connectin | 10 | 2022 | 26 | 1.030 |
Why?
| | Fibroblasts | 5 | 2022 | 842 | 1.020 |
Why?
| | Humans | 183 | 2023 | 118974 | 0.990 |
Why?
| | Precision Medicine | 5 | 2020 | 363 | 0.960 |
Why?
| | Pharmacogenetics | 5 | 2014 | 151 | 0.950 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2023 | 8 | 0.950 |
Why?
| | Glycogen Storage Disease Type IIb | 7 | 2021 | 20 | 0.920 |
Why?
| | Mutation, Missense | 9 | 2021 | 300 | 0.850 |
Why?
| | Heart Ventricles | 13 | 2021 | 727 | 0.850 |
Why?
| | Pedigree | 29 | 2021 | 485 | 0.830 |
Why?
| | Gold | 3 | 2020 | 102 | 0.810 |
Why?
| | Microscopy, Atomic Force | 11 | 2022 | 118 | 0.770 |
Why?
| | Genetic Therapy | 2 | 2017 | 267 | 0.720 |
Why?
| | Prognosis | 19 | 2022 | 3443 | 0.710 |
Why?
| | Metal Nanoparticles | 2 | 2020 | 73 | 0.690 |
Why?
| | Ventricular Remodeling | 4 | 2023 | 229 | 0.670 |
Why?
| | Ventricular Dysfunction, Left | 7 | 2023 | 374 | 0.660 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2022 | 57 | 0.650 |
Why?
| | Dystrophin | 10 | 2020 | 30 | 0.640 |
Why?
| | Plakophilins | 4 | 2023 | 5 | 0.620 |
Why?
| | Ventricular Function | 1 | 2017 | 60 | 0.610 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2016 | 2 | 0.590 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2016 | 19 | 0.590 |
Why?
| | Induced Pluripotent Stem Cells | 2 | 2018 | 185 | 0.570 |
Why?
| | Male | 84 | 2023 | 57801 | 0.560 |
Why?
| | Laminin | 1 | 2016 | 68 | 0.560 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 253 | 0.550 |
Why?
| | Biomimetics | 1 | 2016 | 38 | 0.550 |
Why?
| | Protein Kinases | 4 | 2013 | 310 | 0.540 |
Why?
| | Middle Aged | 55 | 2023 | 27617 | 0.540 |
Why?
| | Embryonic Stem Cells | 1 | 2016 | 114 | 0.530 |
Why?
| | Registries | 15 | 2023 | 1810 | 0.530 |
Why?
| | Cell Adhesion Molecules | 2 | 2023 | 180 | 0.530 |
Why?
| | Defibrillators, Implantable | 4 | 2021 | 299 | 0.520 |
Why?
| | Hydrogels | 2 | 2019 | 582 | 0.520 |
Why?
| | DNA Mutational Analysis | 11 | 2018 | 381 | 0.520 |
Why?
| | Genetic Heterogeneity | 2 | 2009 | 56 | 0.520 |
Why?
| | Stroke Volume | 13 | 2023 | 513 | 0.520 |
Why?
| | Adult | 60 | 2023 | 31512 | 0.510 |
Why?
| | Polymers | 4 | 2022 | 482 | 0.510 |
Why?
| | Ventricular Function, Left | 9 | 2023 | 468 | 0.510 |
Why?
| | Receptors, Endothelin | 2 | 2014 | 49 | 0.510 |
Why?
| | Female | 81 | 2023 | 61565 | 0.500 |
Why?
| | Rats | 12 | 2022 | 5392 | 0.500 |
Why?
| | Receptors, Adrenergic | 1 | 2014 | 36 | 0.490 |
Why?
| | Ventricular Dysfunction, Right | 4 | 2023 | 228 | 0.490 |
Why?
| | Lysine | 1 | 2016 | 248 | 0.480 |
Why?
| | Connexin 43 | 1 | 2014 | 23 | 0.480 |
Why?
| | Animals | 35 | 2022 | 33381 | 0.480 |
Why?
| | Echocardiography | 10 | 2021 | 556 | 0.470 |
Why?
| | src-Family Kinases | 1 | 2014 | 90 | 0.460 |
Why?
| | Valsartan | 3 | 2023 | 22 | 0.450 |
Why?
| | Cardiovascular Agents | 1 | 2014 | 126 | 0.440 |
Why?
| | Genes, Dominant | 12 | 2007 | 96 | 0.440 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1244 | 0.440 |
Why?
| | Cytoskeleton | 7 | 2020 | 181 | 0.440 |
Why?
| | Genetic Association Studies | 5 | 2021 | 371 | 0.410 |
Why?
| | Disease Management | 4 | 2021 | 571 | 0.410 |
Why?
| | Human Genome Project | 1 | 2011 | 16 | 0.410 |
Why?
| | Disease Progression | 5 | 2021 | 2490 | 0.400 |
Why?
| | Myocardial Infarction | 2 | 2019 | 968 | 0.390 |
Why?
| | Nuclear Proteins | 2 | 2009 | 597 | 0.390 |
Why?
| | Gene Expression Regulation | 4 | 2020 | 2445 | 0.370 |
Why?
| | Risk Assessment | 11 | 2020 | 3057 | 0.360 |
Why?
| | Genetic Linkage | 10 | 2001 | 321 | 0.360 |
Why?
| | Cell Differentiation | 2 | 2017 | 1753 | 0.350 |
Why?
| | Desmoplakins | 2 | 2020 | 19 | 0.340 |
Why?
| | Genome, Human | 1 | 2011 | 387 | 0.340 |
Why?
| | Muscular Dystrophies | 2 | 2018 | 36 | 0.340 |
Why?
| | Italy | 13 | 2020 | 90 | 0.330 |
Why?
| | Desmosomes | 3 | 2019 | 19 | 0.330 |
Why?
| | Molecular Biology | 4 | 1997 | 58 | 0.330 |
Why?
| | Cells, Cultured | 9 | 2021 | 4077 | 0.320 |
Why?
| | Chromosome Mapping | 8 | 1997 | 510 | 0.320 |
Why?
| | Lamins | 2 | 2004 | 4 | 0.300 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2020 | 455 | 0.300 |
Why?
| | Myosin Heavy Chains | 3 | 2013 | 192 | 0.290 |
Why?
| | Fibrosis | 4 | 2023 | 483 | 0.290 |
Why?
| | Repressor Proteins | 1 | 2009 | 377 | 0.280 |
Why?
| | Indazoles | 2 | 2022 | 60 | 0.270 |
Why?
| | Genotype | 6 | 2022 | 1882 | 0.270 |
Why?
| | Ventricular Myosins | 1 | 2005 | 33 | 0.260 |
Why?
| | Animals, Newborn | 5 | 2022 | 806 | 0.260 |
Why?
| | Heart Transplantation | 7 | 2020 | 671 | 0.260 |
Why?
| | Risk Factors | 12 | 2022 | 9000 | 0.260 |
Why?
| | Adolescent | 26 | 2023 | 18480 | 0.260 |
Why?
| | Materials Testing | 2 | 2019 | 359 | 0.250 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2478 | 0.240 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2023 | 2 | 0.240 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2004 | 17 | 0.240 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1868 | 0.240 |
Why?
| | Heterozygote | 7 | 2021 | 262 | 0.240 |
Why?
| | Desmin | 2 | 2018 | 31 | 0.240 |
Why?
| | Prealbumin | 1 | 2023 | 23 | 0.240 |
Why?
| | X Chromosome | 8 | 2001 | 47 | 0.240 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2004 | 490 | 0.230 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2016 | 178 | 0.230 |
Why?
| | Progeria | 1 | 2022 | 3 | 0.230 |
Why?
| | Genetic Markers | 4 | 2018 | 348 | 0.220 |
Why?
| | Ethylenediamines | 1 | 2022 | 7 | 0.220 |
Why?
| | Ventricular Function, Right | 2 | 2023 | 257 | 0.220 |
Why?
| | Point Mutation | 4 | 2011 | 228 | 0.220 |
Why?
| | Tachycardia, Ventricular | 3 | 2008 | 151 | 0.220 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 41 | 0.210 |
Why?
| | Chromosomes, Human, Pair 9 | 3 | 1997 | 43 | 0.210 |
Why?
| | Microtechnology | 1 | 2021 | 4 | 0.210 |
Why?
| | Chagas Cardiomyopathy | 1 | 2021 | 21 | 0.200 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2022 | 42 | 0.200 |
Why?
| | Chagas Disease | 1 | 2021 | 34 | 0.200 |
Why?
| | Heart Murmurs | 1 | 2021 | 12 | 0.200 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.200 |
Why?
| | Retrospective Studies | 14 | 2023 | 12978 | 0.190 |
Why?
| | Actinin | 1 | 2020 | 14 | 0.190 |
Why?
| | Neuromuscular Diseases | 1 | 2002 | 90 | 0.190 |
Why?
| | Extracellular Matrix | 2 | 2022 | 446 | 0.190 |
Why?
| | Genomics | 2 | 2017 | 706 | 0.190 |
Why?
| | Gamma Rays | 1 | 2021 | 52 | 0.190 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 3 | 2017 | 11 | 0.190 |
Why?
| | Mechanical Phenomena | 1 | 2021 | 86 | 0.190 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1166 | 0.190 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 76 | 0.190 |
Why?
| | Epidermolysis Bullosa Simplex | 1 | 2020 | 10 | 0.190 |
Why?
| | Time Factors | 10 | 2019 | 6412 | 0.190 |
Why?
| | Heart Diseases | 1 | 2023 | 341 | 0.190 |
Why?
| | Ectodermal Dysplasia | 1 | 2020 | 14 | 0.180 |
Why?
| | Heart Conduction System | 3 | 2016 | 81 | 0.180 |
Why?
| | Mice | 12 | 2022 | 15520 | 0.180 |
Why?
| | Myofibroblasts | 1 | 2021 | 120 | 0.180 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2021 | 80 | 0.180 |
Why?
| | Elastic Modulus | 5 | 2022 | 118 | 0.180 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 32 | 0.180 |
Why?
| | Radiation Injuries | 1 | 2021 | 131 | 0.180 |
Why?
| | Elasticity | 2 | 2017 | 193 | 0.180 |
Why?
| | Double-Blind Method | 3 | 2021 | 1687 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2018 | 453 | 0.180 |
Why?
| | Ankyrins | 1 | 2019 | 7 | 0.180 |
Why?
| | Nanostructures | 1 | 2020 | 100 | 0.180 |
Why?
| | Nanotechnology | 1 | 2020 | 120 | 0.180 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 200 | 0.170 |
Why?
| | Muscular Diseases | 1 | 2000 | 107 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 176 | 0.170 |
Why?
| | Gene Deletion | 2 | 1997 | 361 | 0.170 |
Why?
| | Atrial Fibrillation | 1 | 2003 | 338 | 0.170 |
Why?
| | Membrane Proteins | 2 | 2021 | 1055 | 0.170 |
Why?
| | Immunity, Cellular | 2 | 2018 | 270 | 0.170 |
Why?
| | Actin Cytoskeleton | 2 | 2021 | 100 | 0.170 |
Why?
| | Aged | 24 | 2022 | 19657 | 0.170 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2023 | 107 | 0.170 |
Why?
| | Coculture Techniques | 1 | 2019 | 208 | 0.170 |
Why?
| | Alleles | 1 | 2021 | 832 | 0.170 |
Why?
| | Cytochalasin D | 2 | 2015 | 6 | 0.170 |
Why?
| | Cell Nucleus | 3 | 2019 | 580 | 0.160 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 210 | 0.160 |
Why?
| | Sodium Channels | 2 | 2011 | 63 | 0.160 |
Why?
| | DNA | 2 | 2016 | 1388 | 0.160 |
Why?
| | Contrast Media | 1 | 2021 | 373 | 0.160 |
Why?
| | Skin Physiological Phenomena | 1 | 2017 | 28 | 0.160 |
Why?
| | Myocardial Contraction | 3 | 2018 | 339 | 0.160 |
Why?
| | Intermediate Filaments | 1 | 2017 | 46 | 0.160 |
Why?
| | Cardiac Imaging Techniques | 1 | 2017 | 13 | 0.160 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 150 | 0.160 |
Why?
| | Family Health | 2 | 2011 | 201 | 0.150 |
Why?
| | Young Adult | 10 | 2021 | 10793 | 0.150 |
Why?
| | Gelatin | 1 | 2017 | 35 | 0.150 |
Why?
| | Ion Channels | 1 | 2018 | 126 | 0.150 |
Why?
| | Muscle, Skeletal | 6 | 2005 | 1515 | 0.150 |
Why?
| | Transcriptome | 2 | 2020 | 756 | 0.150 |
Why?
| | Mechanotransduction, Cellular | 1 | 2018 | 101 | 0.150 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 251 | 0.150 |
Why?
| | Prevalence | 8 | 2021 | 2326 | 0.150 |
Why?
| | Internationality | 1 | 2017 | 152 | 0.150 |
Why?
| | Troponin T | 2 | 2013 | 50 | 0.150 |
Why?
| | Vasodilator Agents | 4 | 1988 | 328 | 0.140 |
Why?
| | Odds Ratio | 2 | 2017 | 996 | 0.140 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 95 | 0.140 |
Why?
| | Shear Strength | 1 | 2016 | 55 | 0.140 |
Why?
| | DNA Damage | 1 | 2019 | 357 | 0.140 |
Why?
| | MicroRNAs | 2 | 2020 | 637 | 0.140 |
Why?
| | Cell Proliferation | 4 | 2021 | 2275 | 0.140 |
Why?
| | Multigene Family | 1 | 2017 | 200 | 0.140 |
Why?
| | Exome | 2 | 2017 | 220 | 0.140 |
Why?
| | Keratinocytes | 1 | 2017 | 227 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2019 | 4552 | 0.140 |
Why?
| | Proteomics | 1 | 2022 | 876 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1474 | 0.140 |
Why?
| | Chromosomes, Human, Pair 14 | 4 | 1996 | 17 | 0.140 |
Why?
| | Wolff-Parkinson-White Syndrome | 1 | 2016 | 18 | 0.140 |
Why?
| | Nanofibers | 1 | 2015 | 21 | 0.140 |
Why?
| | Treatment Failure | 1 | 2017 | 341 | 0.140 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 371 | 0.140 |
Why?
| | Polyesters | 1 | 2015 | 65 | 0.130 |
Why?
| | Chromosomes | 1 | 1995 | 87 | 0.130 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2009 | 301 | 0.130 |
Why?
| | Genotyping Techniques | 2 | 2012 | 75 | 0.130 |
Why?
| | DNA Methylation | 1 | 2019 | 503 | 0.130 |
Why?
| | Biopsy | 3 | 2017 | 1079 | 0.130 |
Why?
| | Follow-Up Studies | 13 | 2021 | 4596 | 0.120 |
Why?
| | Spectrum Analysis | 1 | 2015 | 88 | 0.120 |
Why?
| | Propanolamines | 2 | 2009 | 93 | 0.120 |
Why?
| | Logistic Models | 2 | 2017 | 1901 | 0.120 |
Why?
| | Electrocardiography, Ambulatory | 3 | 2015 | 53 | 0.120 |
Why?
| | Catheter Ablation | 2 | 2014 | 286 | 0.120 |
Why?
| | Cell Membrane | 1 | 2018 | 710 | 0.120 |
Why?
| | Heart Aneurysm | 1 | 1994 | 10 | 0.120 |
Why?
| | Cell Culture Techniques | 1 | 2016 | 356 | 0.120 |
Why?
| | Polymerase Chain Reaction | 7 | 2008 | 1012 | 0.120 |
Why?
| | DNA, Mitochondrial | 3 | 2004 | 187 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 734 | 0.120 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 190 | 0.120 |
Why?
| | Genetics | 1 | 2013 | 28 | 0.120 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2013 | 11 | 0.120 |
Why?
| | Cell Enlargement | 1 | 2013 | 5 | 0.120 |
Why?
| | Giant Cells | 1 | 2013 | 22 | 0.120 |
Why?
| | Molecular Sequence Data | 6 | 2014 | 2871 | 0.120 |
Why?
| | Atrioventricular Block | 1 | 2013 | 33 | 0.110 |
Why?
| | Action Potentials | 1 | 2016 | 420 | 0.110 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 40 | 0.110 |
Why?
| | Child | 15 | 2023 | 19129 | 0.110 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2071 | 0.110 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 139 | 0.110 |
Why?
| | Monitoring, Physiologic | 2 | 2021 | 272 | 0.110 |
Why?
| | Heart Rate | 2 | 2016 | 729 | 0.110 |
Why?
| | Cohort Studies | 7 | 2022 | 5116 | 0.110 |
Why?
| | Autophagy | 1 | 2016 | 315 | 0.110 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2021 | 113 | 0.110 |
Why?
| | Biomarkers | 2 | 2023 | 3588 | 0.110 |
Why?
| | American Heart Association | 1 | 2013 | 270 | 0.110 |
Why?
| | Prospective Studies | 9 | 2023 | 6471 | 0.110 |
Why?
| | Survival Rate | 6 | 2021 | 1720 | 0.100 |
Why?
| | Particle Size | 1 | 2013 | 345 | 0.100 |
Why?
| | Electrophysiological Phenomena | 1 | 2012 | 51 | 0.100 |
Why?
| | Surface Properties | 1 | 2013 | 397 | 0.100 |
Why?
| | Nuclear Lamina | 2 | 2020 | 10 | 0.100 |
Why?
| | Biomechanical Phenomena | 3 | 2022 | 683 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1597 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 394 | 0.100 |
Why?
| | Penetrance | 1 | 2011 | 27 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 4 | 2015 | 842 | 0.100 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 755 | 0.100 |
Why?
| | Chromosome Disorders | 3 | 1997 | 39 | 0.100 |
Why?
| | Sex Chromosome Aberrations | 3 | 1997 | 53 | 0.100 |
Why?
| | Equipment Design | 1 | 2013 | 519 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 4 | 2021 | 3174 | 0.100 |
Why?
| | Graft Rejection | 2 | 2004 | 555 | 0.100 |
Why?
| | Chromosome Aberrations | 3 | 1997 | 136 | 0.100 |
Why?
| | Sensitivity and Specificity | 6 | 2015 | 1795 | 0.100 |
Why?
| | Nanoparticles | 1 | 2014 | 325 | 0.090 |
Why?
| | Syndrome | 1 | 2011 | 344 | 0.090 |
Why?
| | Immunosuppressive Agents | 2 | 2004 | 681 | 0.090 |
Why?
| | Family | 2 | 2014 | 585 | 0.090 |
Why?
| | Sarcoidosis | 1 | 2012 | 130 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2015 | 1440 | 0.090 |
Why?
| | Robotics | 1 | 2011 | 83 | 0.090 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1384 | 0.090 |
Why?
| | Cell Division | 1 | 2012 | 776 | 0.090 |
Why?
| | Gene Frequency | 3 | 2017 | 513 | 0.090 |
Why?
| | Genetic Counseling | 2 | 2009 | 66 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 4908 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 1 | 2014 | 461 | 0.090 |
Why?
| | Chromosomes, Human, Pair 3 | 3 | 2004 | 51 | 0.090 |
Why?
| | Sequence Deletion | 3 | 2014 | 171 | 0.090 |
Why?
| | United States | 8 | 2021 | 12555 | 0.090 |
Why?
| | RNA | 3 | 2023 | 833 | 0.090 |
Why?
| | Enterovirus | 3 | 1994 | 72 | 0.090 |
Why?
| | Global Health | 2 | 2014 | 310 | 0.090 |
Why?
| | Disease-Free Survival | 3 | 2015 | 649 | 0.090 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1691 | 0.080 |
Why?
| | Cardiomyopathy, Restrictive | 4 | 1999 | 10 | 0.080 |
Why?
| | Organic Cation Transport Proteins | 1 | 2008 | 28 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2022 | 9342 | 0.080 |
Why?
| | Carnitine | 1 | 2008 | 65 | 0.080 |
Why?
| | Amiodarone | 4 | 2011 | 24 | 0.080 |
Why?
| | Endothelin-1 | 1 | 2009 | 168 | 0.070 |
Why?
| | Consensus | 2 | 2019 | 534 | 0.070 |
Why?
| | Myocarditis | 4 | 1998 | 95 | 0.070 |
Why?
| | Retinitis Pigmentosa | 1 | 2006 | 17 | 0.070 |
Why?
| | Endocardium | 3 | 1999 | 31 | 0.070 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 1997 | 74 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2021 | 3730 | 0.070 |
Why?
| | Myopia | 1 | 2006 | 37 | 0.070 |
Why?
| | Child, Preschool | 6 | 2017 | 9491 | 0.070 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 3 | 2014 | 24 | 0.070 |
Why?
| | Europe | 2 | 2018 | 356 | 0.070 |
Why?
| | Autoimmune Diseases | 3 | 2001 | 398 | 0.070 |
Why?
| | Gene Expression | 3 | 2008 | 1489 | 0.070 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 69 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2018 | 3171 | 0.060 |
Why?
| | Prenatal Diagnosis | 1 | 2006 | 168 | 0.060 |
Why?
| | Conserved Sequence | 1 | 2005 | 219 | 0.060 |
Why?
| | Hemodynamics | 9 | 1992 | 1004 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2013 | 6561 | 0.060 |
Why?
| | NIH 3T3 Cells | 2 | 2015 | 139 | 0.060 |
Why?
| | Homozygote | 2 | 2015 | 190 | 0.060 |
Why?
| | Virus Diseases | 3 | 1998 | 198 | 0.060 |
Why?
| | Cell Shape | 2 | 2015 | 57 | 0.060 |
Why?
| | Primary Prevention | 2 | 2016 | 185 | 0.060 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1323 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 276 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 969 | 0.060 |
Why?
| | Haplotypes | 3 | 2013 | 473 | 0.060 |
Why?
| | Transforming Growth Factors | 1 | 2023 | 3 | 0.060 |
Why?
| | Cataract | 1 | 2006 | 194 | 0.060 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 415 | 0.060 |
Why?
| | Codon, Nonsense | 1 | 2023 | 38 | 0.060 |
Why?
| | Antigens, CD | 2 | 2017 | 460 | 0.060 |
Why?
| | Mass Screening | 1 | 2010 | 1052 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 14 | 1 | 2022 | 6 | 0.060 |
Why?
| | Pregnancy | 3 | 2022 | 5691 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 78 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 228 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2022 | 106 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 1798 | 0.050 |
Why?
| | Genetic Background | 1 | 2021 | 8 | 0.050 |
Why?
| | Optical Tweezers | 1 | 2021 | 20 | 0.050 |
Why?
| | Metoprolol | 2 | 1999 | 37 | 0.050 |
Why?
| | Pyrroles | 1 | 2022 | 191 | 0.050 |
Why?
| | RNA, Messenger | 3 | 2020 | 2657 | 0.050 |
Why?
| | Nanotubes | 1 | 2021 | 41 | 0.050 |
Why?
| | Models, Biological | 2 | 2021 | 1715 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2707 | 0.050 |
Why?
| | Electric Conductivity | 1 | 2020 | 91 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 42 | 0.050 |
Why?
| | Base Sequence | 5 | 2014 | 2159 | 0.050 |
Why?
| | Exercise Test | 4 | 2017 | 551 | 0.050 |
Why?
| | Ferric Compounds | 1 | 2020 | 39 | 0.050 |
Why?
| | Gadolinium | 1 | 2021 | 79 | 0.050 |
Why?
| | Computational Biology | 2 | 2015 | 588 | 0.050 |
Why?
| | Apoptosis | 2 | 2021 | 2484 | 0.050 |
Why?
| | Transfection | 2 | 2017 | 888 | 0.050 |
Why?
| | RNA, Viral | 2 | 1994 | 572 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 462 | 0.050 |
Why?
| | Denmark | 1 | 2019 | 41 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 583 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 410 | 0.040 |
Why?
| | Brazil | 1 | 2019 | 109 | 0.040 |
Why?
| | Maleimides | 1 | 2019 | 23 | 0.040 |
Why?
| | Cell Plasticity | 1 | 2019 | 24 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 180 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 287 | 0.040 |
Why?
| | E2F Transcription Factors | 1 | 2019 | 55 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2019 | 38 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 874 | 0.040 |
Why?
| | Regeneration | 1 | 2020 | 165 | 0.040 |
Why?
| | Heterochromatin | 1 | 2019 | 38 | 0.040 |
Why?
| | Carbazoles | 1 | 1999 | 80 | 0.040 |
Why?
| | CpG Islands | 1 | 2019 | 119 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 164 | 0.040 |
Why?
| | Infant | 4 | 2020 | 8293 | 0.040 |
Why?
| | Canada | 1 | 2019 | 340 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1346 | 0.040 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2018 | 15 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 740 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 481 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2021 | 2874 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2013 | 1125 | 0.040 |
Why?
| | Intercellular Junctions | 1 | 2017 | 34 | 0.040 |
Why?
| | Alginates | 1 | 2018 | 51 | 0.040 |
Why?
| | Age Factors | 2 | 2016 | 2995 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 433 | 0.040 |
Why?
| | Ultrasonography | 2 | 1999 | 716 | 0.040 |
Why?
| | beta Catenin | 1 | 2019 | 219 | 0.040 |
Why?
| | Aorta | 1 | 2000 | 367 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 285 | 0.040 |
Why?
| | Multilevel Analysis | 1 | 2017 | 25 | 0.040 |
Why?
| | Netherlands | 1 | 2017 | 62 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 811 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 522 | 0.040 |
Why?
| | Indoles | 1 | 2019 | 316 | 0.040 |
Why?
| | Biocompatible Materials | 1 | 2020 | 378 | 0.040 |
Why?
| | Bundle-Branch Block | 1 | 2016 | 27 | 0.040 |
Why?
| | Incidence | 3 | 2011 | 2424 | 0.040 |
Why?
| | Cell Movement | 1 | 2021 | 896 | 0.040 |
Why?
| | Gene Editing | 1 | 2017 | 63 | 0.040 |
Why?
| | Molecular Dynamics Simulation | 1 | 2018 | 213 | 0.040 |
Why?
| | Membrane Potentials | 1 | 2017 | 253 | 0.030 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2017 | 154 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 4709 | 0.030 |
Why?
| | Heredity | 1 | 2015 | 11 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2062 | 0.030 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 85 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2017 | 187 | 0.030 |
Why?
| | Sodium | 1 | 2017 | 200 | 0.030 |
Why?
| | Lod Score | 1 | 1995 | 75 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 525 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 604 | 0.030 |
Why?
| | Genes, Recessive | 1 | 1995 | 73 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2015 | 196 | 0.030 |
Why?
| | Cadherins | 1 | 2017 | 186 | 0.030 |
Why?
| | Exons | 2 | 2008 | 307 | 0.030 |
Why?
| | Introns | 1 | 1996 | 234 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1995 | 146 | 0.030 |
Why?
| | Genes, Immunoglobulin | 1 | 1994 | 26 | 0.030 |
Why?
| | Mutagenesis | 1 | 2015 | 176 | 0.030 |
Why?
| | Viscosity | 1 | 2015 | 83 | 0.030 |
Why?
| | Enterovirus Infections | 2 | 1994 | 164 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 100 | 0.030 |
Why?
| | Cytochalasins | 1 | 2014 | 3 | 0.030 |
Why?
| | Quality of Life | 2 | 2023 | 2366 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 625 | 0.030 |
Why?
| | RNA Splicing | 1 | 1996 | 243 | 0.030 |
Why?
| | Tubulin | 1 | 2015 | 122 | 0.030 |
Why?
| | Body Temperature | 1 | 2014 | 215 | 0.030 |
Why?
| | Major Histocompatibility Complex | 1 | 1994 | 220 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2015 | 399 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 1994 | 92 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1994 | 84 | 0.030 |
Why?
| | Cause of Death | 1 | 2015 | 380 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 296 | 0.030 |
Why?
| | Turner Syndrome | 1 | 1994 | 50 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 1994 | 209 | 0.030 |
Why?
| | Ventricular Fibrillation | 1 | 2013 | 51 | 0.030 |
Why?
| | Cardiac Myosins | 1 | 2013 | 33 | 0.030 |
Why?
| | Formaldehyde | 1 | 2013 | 50 | 0.030 |
Why?
| | Skin | 1 | 2017 | 657 | 0.030 |
Why?
| | Electrophysiology | 1 | 2013 | 204 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 467 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2680 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2674 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 2012 | 18 | 0.030 |
Why?
| | Mediastinal Diseases | 1 | 2012 | 9 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1094 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 1047 | 0.030 |
Why?
| | Pacemaker, Artificial | 1 | 2013 | 105 | 0.030 |
Why?
| | Patient Selection | 1 | 2015 | 676 | 0.030 |
Why?
| | Cattle | 1 | 2014 | 978 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1992 | 144 | 0.020 |
Why?
| | Blood Pressure | 2 | 2016 | 1664 | 0.020 |
Why?
| | Antibody Formation | 1 | 1992 | 276 | 0.020 |
Why?
| | Immune System | 1 | 1992 | 181 | 0.020 |
Why?
| | Observer Variation | 1 | 2011 | 309 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2013 | 726 | 0.020 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 965 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 2851 | 0.020 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2009 | 10 | 0.020 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2009 | 22 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2010 | 230 | 0.020 |
Why?
| | Metalloendopeptidases | 1 | 2009 | 56 | 0.020 |
Why?
| | Endothelins | 1 | 2009 | 62 | 0.020 |
Why?
| | Autoimmunity | 1 | 1994 | 831 | 0.020 |
Why?
| | Solute Carrier Family 22 Member 5 | 1 | 2008 | 4 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 1988 | 117 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2009 | 273 | 0.020 |
Why?
| | Cricetulus | 1 | 2008 | 98 | 0.020 |
Why?
| | CHO Cells | 1 | 2008 | 143 | 0.020 |
Why?
| | Death, Sudden | 1 | 1987 | 33 | 0.020 |
Why?
| | Cricetinae | 1 | 2008 | 262 | 0.020 |
Why?
| | Amyloidosis | 1 | 1987 | 40 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2007 | 23 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2006 | 28 | 0.020 |
Why?
| | Electroretinography | 1 | 2006 | 41 | 0.020 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 34 | 0.020 |
Why?
| | Algorithms | 1 | 2013 | 1541 | 0.020 |
Why?
| | Visual Fields | 1 | 2006 | 78 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2006 | 103 | 0.020 |
Why?
| | Models, Genetic | 1 | 2009 | 595 | 0.020 |
Why?
| | Terminology as Topic | 2 | 1999 | 211 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2007 | 412 | 0.020 |
Why?
| | Antimetabolites | 1 | 2004 | 25 | 0.020 |
Why?
| | Growth Inhibitors | 1 | 2004 | 43 | 0.020 |
Why?
| | Societies, Medical | 1 | 2009 | 703 | 0.020 |
Why?
| | Coxsackievirus Infections | 1 | 1984 | 12 | 0.020 |
Why?
| | Azathioprine | 1 | 2004 | 51 | 0.020 |
Why?
| | Everolimus | 1 | 2004 | 64 | 0.020 |
Why?
| | Calcineurin Inhibitors | 1 | 2004 | 61 | 0.020 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 79 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2005 | 345 | 0.020 |
Why?
| | Cyclosporine | 1 | 2004 | 173 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 355 | 0.010 |
Why?
| | Tacrolimus | 1 | 2004 | 151 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4196 | 0.010 |
Why?
| | Sirolimus | 1 | 2004 | 195 | 0.010 |
Why?
| | Captopril | 1 | 1983 | 12 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 823 | 0.010 |
Why?
| | Comorbidity | 1 | 2008 | 1527 | 0.010 |
Why?
| | Proline | 1 | 1983 | 71 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 756 | 0.010 |
Why?
| | Probability | 1 | 2003 | 305 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 403 | 0.010 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 369 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 521 | 0.010 |
Why?
| | Risk | 1 | 2003 | 853 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 1992 | 1794 | 0.010 |
Why?
| | Enterovirus B, Human | 2 | 1993 | 24 | 0.010 |
Why?
| | Chronic Disease | 1 | 1985 | 1636 | 0.010 |
Why?
| | Echocardiography, Doppler | 1 | 1999 | 95 | 0.010 |
Why?
| | World Health Organization | 1 | 1998 | 107 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 195 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1999 | 456 | 0.010 |
Why?
| | Survival Analysis | 2 | 1991 | 1267 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1999 | 586 | 0.010 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1995 | 80 | 0.010 |
Why?
| | Organ Specificity | 1 | 1995 | 278 | 0.010 |
Why?
| | Receptors, Interleukin | 1 | 1994 | 41 | 0.010 |
Why?
| | Gene Amplification | 1 | 1994 | 97 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1994 | 48 | 0.010 |
Why?
| | Fathers | 1 | 1994 | 47 | 0.010 |
Why?
| | Genome, Viral | 1 | 1994 | 124 | 0.010 |
Why?
| | Virology | 1 | 1993 | 20 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1993 | 155 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1993 | 182 | 0.010 |
Why?
| | Interleukins | 1 | 1994 | 242 | 0.010 |
Why?
| | Iodocyanopindolol | 1 | 1992 | 12 | 0.010 |
Why?
| | Pindolol | 1 | 1992 | 16 | 0.010 |
Why?
| | Neuropeptide Y | 1 | 1992 | 12 | 0.010 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1992 | 32 | 0.010 |
Why?
| | Adenylyl Cyclases | 1 | 1992 | 86 | 0.010 |
Why?
| | Catecholamines | 1 | 1992 | 100 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 565 | 0.010 |
Why?
| | Isoproterenol | 1 | 1992 | 125 | 0.010 |
Why?
| | Autoantigens | 1 | 1994 | 397 | 0.010 |
Why?
| | Complement System Proteins | 1 | 1994 | 294 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1158 | 0.010 |
Why?
| | DNA, Viral | 1 | 1993 | 356 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1994 | 632 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1995 | 1323 | 0.010 |
Why?
| | Felodipine | 1 | 1988 | 4 | 0.010 |
Why?
| | Nitrendipine | 1 | 1988 | 13 | 0.010 |
Why?
| | Nisoldipine | 1 | 1988 | 6 | 0.010 |
Why?
| | Nicardipine | 1 | 1988 | 6 | 0.010 |
Why?
| | Diltiazem | 1 | 1988 | 22 | 0.010 |
Why?
| | Nifedipine | 1 | 1988 | 29 | 0.010 |
Why?
| | Verapamil | 1 | 1988 | 32 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1999 | 5255 | 0.010 |
Why?
| | Statistics as Topic | 1 | 1989 | 307 | 0.010 |
Why?
| | Autoantibodies | 1 | 1994 | 1335 | 0.000 |
Why?
| | Cardiomyopathy, Alcoholic | 1 | 1985 | 1 | 0.000 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1985 | 70 | 0.000 |
Why?
| | Physical Exertion | 1 | 1986 | 222 | 0.000 |
Why?
| | Heart Septal Defects | 1 | 1984 | 10 | 0.000 |
Why?
| | Cardiac Output | 1 | 1984 | 147 | 0.000 |
Why?
| | Cardiac Catheterization | 1 | 1987 | 541 | 0.000 |
Why?
| | Vascular Resistance | 1 | 1984 | 356 | 0.000 |
Why?
| | Coronary Disease | 1 | 1984 | 356 | 0.000 |
Why?
| | Ethanol | 1 | 1985 | 575 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1984 | 542 | 0.000 |
Why?
| | Hypertension | 1 | 1985 | 1203 | 0.000 |
Why?
|
|
Mestroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|